The FDA's Center for Drug Evaluation and Research named Lisa Yanoff acting deputy director on July 6, 2026, moving a longtime GLP-1 receptor agonist reviewer into senior leadership. The appointment, selected by Acting Director Michael Davis, took effect immediately, and no timeline for a permanent…
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research announced on July 6, 2026, that Lisa Yanoff, a longtime reviewer of GLP-1 receptor agonists and metabolic therapies, had been promoted to acting deputy director. The promotion took effect immediately, and Yanoff has already begun her new duties. The selection was made by CDER Acting Director Michael Davis, and Yanoff will report directly to him.
The move places at the center of American drug regulation a reviewer whose professional identity is bound up with the most commercially consequential peptide drug class of the past two decades. CDER oversees the approval and monitoring of every prescription and over-the-counter drug sold in the United States, which makes the deputy director position one of the most consequential seats in the agency's leadership structure.
Yanoff has spent many years at the FDA and is well known within the agency for her work on GLP-1 receptor agonists, according to the announcement. The announcement also characterized her as a natural choice for the position. That characterization originates with the agency itself and has not been independently established, but her long review career and her focus on metabolic therapies are stated facts, and they are the evident basis for the selection.
Yanoff's duties as acting deputy director are defined by the center's core functions. She will help guide the review of new drug applications and work to ensure regulatory consistency across CDER. Those two mandates are the daily substance of the center's work, and they operate at different levels of granularity.
Guiding new drug application review places her in the chain of decision for every original drug application that reaches the agency, which includes the metabolic and peptide products where her expertise is concentrated. Ensuring regulatory consistency is the broader mandate. It means reconciling how different review offices within CDER apply the same statutory standards to different therapeutic areas, how they weigh benefit and risk, and how they enforce post-marketing commitments. Inconsistency between divisions is a chronic risk in any large regulatory body, and the deputy director is one of the positions charged with preventing it.
The appointment is an acting one, not permanent, and the FDA has not announced a timeline for a permanent appointment to the deputy director position. That leaves the length of Yanoff's tenure unspecified. Acting appointments can run for extended stretches while the agency works through the selection and clearance process, but they carry an expectation of impermanence that shapes how staff and outside sponsors treat the officeholder's directives.
The selection of Yanoff sits in a specific institutional context. Davis, who chose her, is himself an acting director, so both of the center's top two positions are held by acting officeholders. That arrangement is not unusual for the FDA, where leadership transitions frequently outpace the confirmation calendar, but it does mean that policy decisions made now will be inherited by whatever permanent leadership eventually takes over.
The larger context is the drug class itself. GLP-1 receptor agonists have grown significantly in prominence for treating type 2 diabetes and obesity, and the promotion reflects CDER's increased attention on drugs for diabetes, obesity, and related metabolic conditions. Placing a GLP-1 reviewer in the deputy director's office is the kind of personnel decision that agencies make when a therapeutic category has become central to their workload.
CDER is the largest of the FDA's product-centered centers. Its statutory coverage includes new drug applications for innovator products, abbreviated new drug applications for generics, over-the-counter drug monographs, and the post-marketing surveillance of every approved drug. When a sponsor submits a new drug application, CDER staff evaluate the preclinical pharmacology and toxicology, the clinical trial evidence, the chemistry, manufacturing and controls package, and the proposed labeling, and the center's decision determines whether the product may be marketed at all.
The legal standard for approval is substantial evidence of effectiveness from adequate and well-controlled studies, together with a finding that the drug's benefits outweigh its risks. That standard sounds simple and is anything but. Applying it to a peptide drug requires judgments about trial endpoints, comparator choice, statistical analysis, and the clinical meaningfulness of measured effects, and those judgments are where a reviewer's therapeutic-area knowledge becomes decisive.
The deputy director sits below the director and above the individual review offices. The position is not the deciding vote on any single application; the authority to approve or reject resides in the review divisions and in the center director's sign-off. But the deputy director's influence operates through other channels: resolving disputes between offices, allocating review staff, shaping the center's interpretation of FDA guidance, and setting the tone for how the agency engages with sponsors.
Acting appointments exist to keep that machinery running when permanent positions are vacant or in transition. They allow the agency to place a qualified person in a senior role without waiting for the Senate confirmation process, which for a position of this rank can consume many months. The cost is the provisional character of the appointment, which can limit the officeholder's appetite for long-horizon initiatives and give staff a reason to hesitate before committing to policy changes.
The choice of a metabolic drug reviewer for the deputy director post tracks the actual composition of CDER's workload. GLP-1 receptor agonists are now among the most prescribed drug classes in the country, and the review pipeline for metabolic and peptide-based therapies extends well beyond the current generation of products. A center leadership that understands the biology, chemistry, and clinical science of those drugs is positioned to review them competently. A center leadership that did not would face a steep learning curve at exactly the moment the class matters most.
Understanding why Yanoff's background matters for the deputy director role requires a close look at the drug class that defined her career. Glucagon-like peptide-1 is an incretin hormone secreted by intestinal L cells in response to food intake. It binds to the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, where it potentiates glucose-dependent insulin secretion, and on pancreatic alpha cells, where it suppresses glucagon release.
The glucose dependence of the insulin response is the pharmacological feature that distinguishes the class from older insulin secretagogues. When blood glucose is elevated, the receptor signal amplifies insulin release; when glucose is normal or low, the effect recedes. That built-in safety property is why GLP-1 receptor agonists carry a low risk of hypoglycemia in the absence of other glucose-lowering drugs, and it has shaped the class's clinical positioning since the first approvals.
The receptor is expressed beyond the pancreas. In the gastrointestinal tract, GLP-1 signaling slows gastric emptying, which delays nutrient absorption and contributes to post-meal glucose control. In the central nervous system, particularly in hypothalamic nuclei involved in appetite regulation, GLP-1 signaling reduces food intake and increases satiety. Those actions produce the two clinical effects that have made the class famous: glycemic control in type 2 diabetes and weight loss in obesity. The same gastrointestinal action generates the nausea, vomiting, and delayed gastric emptying that are the class's most common adverse effects, and managing those effects has driven dosing strategies, titration schedules, and trial design across the entire drug family.
The peptide chemistry is the part that makes GLP-1 receptor agonists a peptide story. Native GLP-1 has a plasma half-life of roughly two minutes because the enzyme dipeptidyl peptidase-4 cleaves it at its N-terminus and because the kidney clears the resulting fragments rapidly. Native GLP-1 cannot serve as a practical injected medicine. Every marketed agonist is an engineered analog that resists DPP-4 cleavage, extends its circulating half-life, or both.
The engineering strategies are instructive for anyone watching the peptide field. Substituting the amino acid at position two of the peptide blocks the DPP-4 cleavage site. Fatty acid acylation, in which a lipid chain is attached to a lysine residue, promotes reversible binding to serum albumin, creating a circulating depot that stretches the dosing interval from twice daily to once weekly. Other modifications increase receptor affinity, resist additional proteases, or alter solubility. The result is a family of peptide drugs, most in the range of thirty to forty amino acids, each with a distinct pharmacokinetic profile, immunogenicity risk, and manufacturing challenge.
A reviewer who has spent years on this class has had to master all of those dimensions: the physiology of the incretin system, the degradation pathways that limit peptide half-life, the aggregation and stability problems that complicate peptide formulation, and the clinical trial designs needed to demonstrate glycemic and weight effects. That is specialized knowledge, and it is now seated in the deputy director's office. Whether it translates into policy change is a separate question, addressed below, but the knowledge itself is not in question.
For researchers developing peptide-based metabolic drugs, the immediate practical effect of the appointment is signal. The signal is that CDER's senior leadership includes someone who understands the scientific particularities of peptide therapeutics: short native half-lives, enzymatic degradation, immunogenicity, and the manufacturing burden of producing consistent peptide product at scale. Sponsors can expect those concerns to be represented in senior-level review discussions rather than treated as peripheral technicalities.
For the broader peptide pipeline, the relevance extends beyond the GLP-1 class itself. Development activity in metabolic disease has moved toward multi-target peptides: dual agonists that activate the GLP-1 receptor alongside the glucose-dependent insulinotropic polypeptide receptor or the glucagon receptor, and combination regimens involving amylin analogs and other peptide hormones. Those molecules raise review questions that a GLP-1 specialist is well equipped to handle, but they also raise new ones, particularly around additive toxicity, dose titration, and cardiovascular risk assessment.
For clinicians, the practical stakes involve access and predictability. The deputy director's office influences how quickly new drug applications move through review, how post-marketing requirements are framed, and how the agency coordinates responses to supply disruptions. GLP-1 receptor agonists have faced documented supply shortages as demand has strained manufacturing capacity, and managing those shortages requires coordination across review offices, compliance offices, and the agency's drug shortage program. The consistency mandate attached to Yanoff's role is directly relevant to that kind of coordination.
For the peptide supply chain, the relevant question is quality expectations. Peptide manufacturing is exacting. It involves solid-phase synthesis, chromatographic purification, formulation, and control of process-related impurities, all under current good manufacturing practice. How CDER applies chemistry,…
Peptides referenced: Amylin, Glucagon, GLP-1.
Related reading: ADA 2026 Obesity Drug Updates: Retatrutide, CagriSema, Oral GLP-1s, Bachem Holding Secures ImmuPharma Manufacturing Win, Bachem Holding AG Details Peptide Growth Strategy Amid Biotech Demand Rise, Ascletis Submits Two Obesity IND Applications to U.S. FDA.